Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer.

"CONFLICTS OF INTEREST J.P.L. received research funding from Kazia Therapeutics and consulting honoraria from Minerva Biotechnologies. S.M.T. receives institutional research funding from AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Exelixis, Bristol‐Myers Squibb, Eisai, Nanostring, Cyclacel, Odonate, Sanofi, and Seattle Genetics; has served as an advisor/consultant to, and/or received honoraria from, AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics/Gilead, Bristol‐Myers Squibb, Eisai, Nanostring, Puma, Sanofi, Silverback Therapeutics, G1 Therapeutics, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Daiichi‐Sankyo, Ellipsis, Infinity, 4D Pharma, Samsung Bioepsis Inc, Chugai Pharmaceuticals, BeyondSpring Pharmaceuticals, OncXerna, OncoSec Medical Incorporated, Odonate, Certara, Mersana Therapeutics, CytomX, Zymeworks, Zentalis, Blueprint Pharmaceuticals, and Seattle Genetics. E.P.W. reports institutional research funding from Genentech/Roche; serving as a consultant for Athenex, Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, Gilead, GlaxoSmithKline, GSK, Jounce, Lilly, St. Lucia, Syros, and Zymeworks; a nonpaid scientific advisory board membership at Leap Therapeutics; and serving as President‐Elect of the American Society of Clinical Oncology (ASCO). N.U.L. reports institutional research funding from Genentech, Merck, Pfizer, Seattle Genetics, AstraZeneca, Zion Pharmaceuticals, and Olema Pharmaceuticals; consultant/advisory board work for Pfizer, Puma, Seattle Genetics, Daiichi Sankyo, AstraZeneca, Prelude Therapeutics, Denali Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, and Artera, Inc; royalties from UpToDate; and stock or other ownership interests in Artera Inc (a startup with no current value, but options only valued at <5% and < $50,000 will be provided at a later date). The remaining authors made no disclosures."